Mucosal immune responses following oral immunization with rotavirus antigens encapsulated in alginate microspheres.
Availability of effective oral vaccine delivery vehicles should contribute to the success of oral immunization in domestic animals. To achieve this goal, we evaluated alginate microspheres for their capacity to induce mucosal immune responses following oral and enteric immunizations. Mice were immunized with either live porcine rotavirus (PRV) or its recombinant VP6 protein, encapsulated in alginate microspheres or unencapsulated. VP6-specific IgG (but no IgA) antibodies were detected in the sera of mice after a single intraperitoneal (i.p.) immunization with either VP6 in Incomplete Freund's adjuvant (VP6-IFA), VP6 in alginate microspheres (VP6-MS) or with live PRV in incomplete Freund's adjuvant (PRV-IFA). In contrast, VP6-specific IgA (but no IgG) was detected in culture supernatants of mesenteric lymph nodes from mice immunized i.p. with either VP6-IFA or with PRV-IFA. Oral immunization with VP6-MS induced the highest level of VP6-specific fecal IgA antibody, similar to responses induced by oral immunization with live PRV. Furthermore, the VP6-specific fecal IgA could be boosted by a secondary i.p. immunization with VP6. Further experiments were performed in a sheep intestinal 'loop' model to evaluate uptake of microspheres by Peyer's patches. Microspheres containing colloidal carbon were specifically bound and transported by follicle-associated epithelium of Peyer's patches. Additionally, mucosal immune responses were detected following enteric immunization with porcine serum albumin (PSA) encapsulated in alginate microspheres. Our results confirm that alginate microspheres are an effective oral delivery vehicle for protein antigens and intestinal IgA antibody responses are induced by antigens encapsulated in alginate microspheres without any additional mucosal adjuvant. These investigations confirm that alginate microspheres have the potential as an effective delivery vehicle for oral immunization of ruminants.
Kim
B
B
Veterinary Infectious Disease Organization, University of Saskatchewan, 120 Veterinary Road, Saskatchewan, Saskatoon, Canada S7N 5E3.
Bowersock
T
T
Griebel
P
P
Kidane
A
A
Babiuk
L A
LA
Sanchez
M
M
Attah-Poku
S
S
Kaushik
R S
RS
Mutwiri
G K
GK
D000284:Administration, Oral; D000464:Alginates / Q000008:administration & dosage*; D000818:Animals; D000956:Antigens, Viral / Q000008:administration & dosage* / Q000276:immunology; D004339:Drug Compounding; D020723:Glucuronic Acid; D006603:Hexuronic Acids; D007070:Immunoglobulin A / Q000276:immunology; D007074:Immunoglobulin G / Q000276:immunology; D007413:Intestinal Mucosa / Q000187:drug effects / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008863:Microspheres; D012401:Rotavirus / Q000276:immunology*; D012756:Sheep; D013552:Swine
D000464:Alginates; D000956:Antigens, Viral; D006603:Hexuronic Acids; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D020723:Glucuronic Acid